SSSatender Pal Singh

Satender Pal Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Satender Pal Singh has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictors of Non-response to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma: A Multicentre Real World Study (HCC-AB Study)

    by Satender P. Singh, Karan Kumar, Anand Kulkarni, Vinod Arora, Ashok Choudhury, Alisha Chaubal, Sahaj Rathi, Samir Shah, Sunil Taneja, Ashish Kumar, et al.


  • Bowel Colonization With Carbapenem‐Resistant Bacteria Is Associated With Short‐Term Outcomes in Patients With Acute‐On‐Chronic Liver Failure

    by Satender Pal Singh, Vikram Bhatia, Pratibha Kale, Guresh Kumar, Vikas Khillan, Rajan Vijayaraghavan

    Background: Bowel colonization with antimicrobial‐resistant bacteria has been associated with worse clinical outcomes in patients with cirrhosis; however, it has not been studied in patients with acute‐on‐chronic liver failure (ACLF). We evaluated whether fecal isolation of carbapenem‐resistant gram‐negative bacteria (CR‐GNB) among patients with ACLF affects short‐term outcomes.Methods: Patients of APASL‐ACLF (n = 339) were screened between June 2020 and December 2021, and 150 were included. Stool cultures were carried out at baseline and every 5 days thereafter until discharge or death. All surviving patients were followed until 60 days after discharge.Results: Mean age was 44.8 (8.8) years, with 86% males and alcohol as etiology in 66%. CR‐GNB organisms were isolated from stool in 42% of hospitalized ACLF patients, with E. coli and Klebsiella pneumoniae as the most common species. Patients with CR‐GNB fecal carriage were associated with higher CTP, MELD, and DF scores but not with recent antibiotics, proton pump inhibitors, or lactulose use. Extraintestinal infections developed in 59.3% overall, most commonly UTI, pneumonia, and SBP. Infectious complications developed in 57.3% and 19.7% with and without CR‐GNB in the stool (RR: 5.5; p < 0.001). Peripheral cultures were positive in 60.7% with infections, with species concordant with the fecal isolates found in 90.7%. Isolation of CR‐GNB from stool and high bilirubin were independently associated with both in‐hospital mortality and 60‐day mortality (p = 0.05).Conclusions: Hospitalized ACLF patients with CR‐GNB in the stool have a significantly higher risk of extraintestinal infections, in‐hospital mortality, and short‐term mortality up to 60 days.Trial Number: [NCT04383106].


  • Top Cited Papers

    Global Epidemiology of Hepatocellular Carcinoma

    by Satender P. Singh, Tushar Madke, Phool Chand


  • Post-Liver Transplant Metabolic Syndrome

    by Ashok Choudhury, Satender P. Singh, Akhil Desmukh, Bishnupriya Sahoo, Mohammed Eslam


  • Comparative metabolome analysis reveals higher potential of haemoperfusion adsorption in providing favourable outcome in ACLF patients

    by Manisha Yadav, Rakhi Maiwal, Vinay Kumar Br, Gaurav Tripathi, Neha Sharma, Nupur Sharma, Vasundhra Bindal, Babu Mathew, Sushmita Pandey, Satender Pal Singh, et al.

    Background and Aims: Acute‐on‐chronic liver failure (ACLF) is a serious illness associated with altered metabolome, organ failure and high mortality. Need for therapies to improve the metabolic milieu and support liver regeneration are urgently needed.Methods: We investigated the ability of haemoperfusion adsorption (HA) and therapeutic plasma exchange (TPE) in improving the metabolic profile and survival in ACLF patients. Altogether, 45 ACLF patients were randomized into three groups: standard medical therapy (SMT), HA and TPE groups. Plasma metabolomics was performed at baseline, post‐HA and TPE sessions on days 7 and 14 using high‐resolution mass spectrometry.Results: The baseline clinical/metabolic profiles of study groups were comparable. We identified 477 metabolites. Of these, 256 metabolites were significantly altered post 7 days of HA therapy (p < .05, FC > 1.5) and significantly reduced metabolites linked to purine (12 metabolites), tryptophan (7 metabolites), primary bile acid (6 metabolites) and arginine‐proline metabolism (6 metabolites) and microbial metabolism respectively (p < .05). Metabolites linked to taurine‐hypotaurine and histidine metabolism were reduced and temporal increase in metabolites linked to phenylalanine and tryptophan metabolism was observed post‐TPE therapy (p < .05). Finally, weighted metabolite correlation network analysis (WMCNA) along with inter/intragroup analysis confirmed significant reduction in inflammatory (tryptophan, arachidonic acid and bile acid metabolism) and secondary energy metabolic pathways post‐HA therapy compared to TPE and SMT (p < .05). Higher baseline plasma level of 11‐deoxycorticosterone (C03205; AUROC > 0.90, HR > 3.2) correlated with severity (r2 > 0.5, p < .05) and mortality (log‐rank‐p < .05). Notably, 51 of the 64 metabolite signatures (ACLF non‐survivor) were reversed post‐HA treatment compared to TPE and SMT(p < .05).Conclusion: HA more potentially (~80%) improves plasma milieu compared to TPE and SMT. High baseline plasma 11‐deoxycorticosterone level correlates with early mortality in ACLF patients.


  • Open Access

    Cytological Diagnosis of Castleman Disease by Endoscopic Ultrasound Guided Fine Needle Aspiration

    by Vikram Bhatia, Satender Pal Singh, Ajay Kumar Mishra, Indira Rath, Meghana Prabhu, Chhagan Bihari

    Castleman disease is a nonmalignant, lymphoproliferative disorder. Unicentric disease type involves a single enlarged lymph node or nodal regions, and multicentric disease involves multiple lymph node site involvement. We present a case of 26-year-old young female presented to outpatient with complaint of generalized weakness and abdominal pain for last 2 months. Her imaging included positron emission computed tomography which showed soft-tissue mass along the body of pancreas. Endoscopic ultrasound done showed nodal mass with extensive calcification and doppler endoscopic ultrasound showing arborising vessels. Fine needle aspiration cytology (FNAC) and biopsy taken showed lymphoid cells and diffuse hyaline material. After suboptimal response to chemotherapy regimen, she underwent open laparotomy and excision of the retroperitoneal mass.


  • Open Access

    Comparison of Balloon-Occluded Thrombolysis with Catheter-Directed Thrombolysis in Patients of Budd-Chiari Syndrome with Occluded Direct Intrahepatic Portosystemic Shunt

    by Amar Mukund, Tanya Yadav, Satender Pal Singh, Saggere Muralikrishna Shasthry, Rakhi Maiwall, Yashwant Patidar, Shiv Kumar Sarin

    Objectives Direct intrahepatic portosystemic shunt (DIPS) stent placement is an effective treatment for patients with Budd-Chiari syndrome (BCS); however, thrombotic occlusion of DIPS stent remains a cause of concern. The purpose of this study is to describe a novel technique of balloon-occluded-thrombolysis (BOT) for occluded DIPS stent, and compare it with the conventional catheter-directed-thrombolysis (CDT). Methods In this retrospective study, the hospital database was searched for BCS patients who underwent DIPS revision for thrombotic stent occlusion between January 2015 and February 2021. Patients were divided into CDT group and BOT group. The groups were compared for technical success, total dose of thrombolytic agent administered, duration of hospital stay, and primary assisted stent patency rates at 1- and 6-month follow-up. Results CDT was performed in 12 patients, whereas 21 patients underwent BOT. Complete recanalization was achieved in 66.7% (8 of 12) patients of CDT group as compared to 81% (17 of 21) patients of BOT group (nonsignificant difference, p = 0.420). BOT group had a short hospital stay (1.8 ± 0.7 vs. 3.5 ± 1.0 days) and required less dose of thrombolytic agent ([2.2 ± 0.4]x105 IU versus [8.3 ± 2.9]x105 IU of urokinase) as compared to the CDT group and both differences were statistically significant (p < 0.001). Further, 6-month patency rate was higher in BOT group as compared to CDT group (p = 0.024). Conclusion The novel BOT technique of DIPS revision allows longer contact time of thrombolytic agent with the thrombi within the occluded stent. This helps in achieving fast recanalization of thrombosed DIPS stent with a significantly less dose of thrombolytic agent required, thus reducing the risk of systemic complications associated with thrombolytic administration. A.M. was involved in conceptualization, methodology, reviewing, editing and finalizing the manuscript. T.Y. helped in data curation, data analysis, preparation of first draft of the manuscript. S.P.S. helped in data Curation and reviewing the manuscript. S.M.S. contributed to patient enrolling, clinical management, and methodology. R.M. helped in patient enrolling, clinical management, and data analysis. Y.P. helped in imaging evaluation of patients and reviewing the manuscript. S.K.S. was involved in supervising the research, reviewing, and editing to reach the final version of manuscript. Clinical trials.gov ID: NCT05117684. Approval for the study was obtained from institutional review board (IEC/2021/86/MA15). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study has obtained IRB approval from (IEC/2021/86/MA15) and the need for informed consent was waived. Consent for publication was obtained for every individual person's data included in the study. Article published online: 26 June 2023 © 2023. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India


  • MELD 3.0: A better score for liver allocation?

    by Satender Pal Singh, Rakhi Maiwall

    An abstract is unavailable. This article is available as a PDF only.


  • Adrenal Insufficiency Associated with Low High-Density Lipoprotein (HDL) in Patients of Chronic Liver Disease

    by Satender Pal Singh, Nitisha Mondia

    Introduction: Adrenal insufficiency is noted in patients of cirrhosis, mainly in critically ill patients. Cirrhosis characterized with low synthetic functions has multiple indirect markers for severity. Methodology: 100 decompensated cirrhosis patients were hospitalized to Lady Hardinge Medical College in New Delhi as part of an observational cohort research from October 2014 to June 2016. Adrenocorticotrophic hormone stimulation test was done with 250 mcg, basal cortisol, and cortisol after 60 minutes of stimulation was noted. We investigated the relationship between blood HDL levels and adrenal insufficiency. Results: Insufficient adrenal function was detected in 28% of the patients. INR, serum total bilirubin, serum creatinine, low high-density lipoprotein (HDL), child score, MELD score, plasma renin activity level, and renal resistive index were all associated with patients with adrenal insufficiency on univariate analysis. Multivariate analysis showed in patients with adrenal insufficiency, MELD score had odds ratio of 1.5 with AUC 0.724 (0.622-0.825), Bilirubin with odds ratio of 5.6 and AUC of 0.676 (0.679-0.882). Serum HDL with odds ratio of 6.1 (3.3-9.2) and AUC 0.822 (0.724-0.828) with P value <0.001, cut off calculated was 26 mg/dL with sensitivity of 81% and specificity of 85% predicts adrenal insufficiency. Patients with adrenal insufficiency had higher mortality. Conclusion: Cirrhosis is associated with adrenal insufficiency, more with advanced liver disease. Low HDL level in blood can be taken as an indirect marker for adrenal insufficiency.